Trial Profile
A Pilot Study Combining Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions
- 23 Nov 2021 Status changed from active, no longer recruiting to completed.
- 13 Jan 2021 Planned End Date changed from 30 Nov 2021 to 25 Aug 2021.
- 10 Jul 2020 Planned End Date changed from 31 May 2021 to 30 Nov 2021.